State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
University of Chinese Academy of Sciences, Beijing, China.
Cell Prolif. 2020 Dec;53(12):e12938. doi: 10.1111/cpr.12938. Epub 2020 Oct 29.
Premature ovarian insufficiency (POI) is a refractory disease that seriously affects female fertility. Growing body of evidence has indicated mesenchymal stem cells (MSCs) as promising resources in regenerative medicine. In this study, we treated POI patients with umbilical cord-derived MSCs (UCMSCs) and then investigated the restoration of ovarian function and clinical outcomes through follow-ups.
Sixty-one patients diagnosed with POI participated in this study. UCMSCs were isolated and cultured according to GMP standards, and then transplanted to the patients' ovary by orthotopic injection under the guidance of vaginal ultrasound. We monitored side effects, vital signs and changes in clinical and collected haematological and imaging parameters during the follow-ups.
All patients showed normal clinical behaviour without serious side effects or complications relevant to the treatment. Transplantation of UCMSCs rescued the ovarian function of POI patients, as indicated by increased follicular development and improved egg collection. POI patients who experienced shorter amenorrhoea durations (<1 year) seemed to obtain mature follicles more easily after stem cell therapy, and patients with better ovarian conditions (pre-operative antral follicles) were more likely to derive the better outcomes by UCMSC injection. Four successful clinical deliveries were obtained from POI patients after UCMSC transplantation, and all of these babies are developed normally.
The clinical trial result sugggests a possible therapy for POI by UCMSC transplantation.
卵巢早衰（POI）是一种难治性疾病，严重影响女性生育能力。越来越多的证据表明间充质干细胞（MSCs）是再生医学中有前途的资源。在这项研究中，我们用脐带间充质干细胞（UCMSCs）治疗 POI 患者，然后通过随访调查卵巢功能恢复和临床结果。
61 名被诊断为 POI 的患者参与了这项研究。根据 GMP 标准分离和培养 UCMSCs，然后在阴道超声引导下通过原位注射将其移植到患者的卵巢中。我们监测副作用、生命体征以及临床变化，并在随访期间收集血液学和影像学参数。
所有患者均表现出正常的临床行为，无与治疗相关的严重副作用或并发症。UCMSCs 的移植挽救了 POI 患者的卵巢功能，表现为卵泡发育增加和卵子采集改善。接受干细胞治疗的 POI 患者中，闭经时间较短（<1 年）的患者似乎更容易获得成熟卵泡，卵巢状况较好（术前窦卵泡）的患者通过 UCMSC 注射更有可能获得更好的结果。POI 患者在 UCMSC 移植后有 4 例成功临床分娩，所有婴儿均发育正常。
临床试验结果提示 UCMSC 移植可能是治疗 POI 的一种方法。
